Biotech Valuation Message Board

Sponsor

To: Biomaven who wrote (32621)	10/15/2009 8:31:08 AM
From: IRWIN JAMES FRANKEL	2 Recommendations of 40274

>>Have to believe that is hit or miss. Extended release is hard enough to do when it's designed-in to the product. Investigator IJF Study: I have a huge sample size, n=1, long study 2 weeks, a responder and product of a single compounder. The data is uniform. ;-) I was skeptical that the compounded product would have a sufficiently long half life to allow practical dosing because I understood that 4AP had a relatively short half life (something like 3-4 hours). Both the neuro and the compounder claimed extended effect. I was surprised that a single 5mg dose was still providing clinically significant benefit the next morning. At 5mg bid dosing (breakfast and dinner) there is continuous clinically significant benefit. ij